<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00994500</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-01980</org_study_id>
    <secondary_id>ADVL0916</secondary_id>
    <secondary_id>CDR0000656719</secondary_id>
    <secondary_id>COG-ADVL0916</secondary_id>
    <secondary_id>U01CA097452</secondary_id>
    <nct_id>NCT00994500</nct_id>
  </id_info>
  <brief_title>Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma</brief_title>
  <official_title>A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of vorinostat when given&#xD;
      together with bortezomib in treating young patients with refractory or recurrent solid&#xD;
      tumors, including CNS tumors and lymphoma. Vorinostat and bortezomib may stop the growth of&#xD;
      tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow&#xD;
      to the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum-tolerated dose and/or recommended phase II dose of vorinostat in&#xD;
      combination with bortezomib in pediatric patients with refractory or recurrent solid tumors,&#xD;
      including central nervous system tumors and lymphoma.&#xD;
&#xD;
      II. To define and describe the toxicities of this regimen in these patients. III. To&#xD;
      characterize the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To preliminarily define the antitumor activity of this regimen within the confines of a&#xD;
      phase I study.&#xD;
&#xD;
      II. To assess the biologic activity of bortezomib by measuring NF-κB activity in peripheral&#xD;
      blood mononuclear cells (PBMC).&#xD;
&#xD;
      III. To assess the biologic activity of bortezomib by measuring endoplasmic reticulum stress&#xD;
      response using the GRP78 molecular chaperone marker in PBMC.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of vorinostat.&#xD;
&#xD;
      Patients receive oral vorinostat once daily on days 1-5 and 8-12 and bortezomib IV over 3-5&#xD;
      seconds on days 1, 4, 8, and 11. Courses repeat every 21 days for up to 2 years in the&#xD;
      absence of disease progression or unacceptable toxicity. Blood samples are collected at&#xD;
      baseline and during course 1 of study for further analysis.&#xD;
&#xD;
      After completion of study therapy, patients are followed up within 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose defined as the maximum dose at which fewer than one-third of patients experience DLT according to NCI CTCAE version 3.0</measure>
    <time_frame>21 days</time_frame>
    <description>In addition to determination of the MTD, a descriptive summary of all toxicities will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease response assessed according to RECIST criteria</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Will be reported descriptively.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Childhood Burkitt Lymphoma</condition>
  <condition>Childhood Central Nervous System Choriocarcinoma</condition>
  <condition>Childhood Central Nervous System Germ Cell Tumor</condition>
  <condition>Childhood Central Nervous System Germinoma</condition>
  <condition>Childhood Central Nervous System Mixed Germ Cell Tumor</condition>
  <condition>Childhood Central Nervous System Teratoma</condition>
  <condition>Childhood Central Nervous System Yolk Sac Tumor</condition>
  <condition>Childhood Choroid Plexus Tumor</condition>
  <condition>Childhood Craniopharyngioma</condition>
  <condition>Childhood Diffuse Large Cell Lymphoma</condition>
  <condition>Childhood Immunoblastic Large Cell Lymphoma</condition>
  <condition>Childhood Medulloepithelioma</condition>
  <condition>Childhood Meningioma</condition>
  <condition>Childhood Mixed Glioma</condition>
  <condition>Childhood Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Childhood Oligodendroglioma</condition>
  <condition>Recurrent Childhood Anaplastic Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Brain Stem Glioma</condition>
  <condition>Recurrent Childhood Central Nervous System Embryonal Tumor</condition>
  <condition>Recurrent Childhood Cerebellar Astrocytoma</condition>
  <condition>Recurrent Childhood Cerebral Astrocytoma</condition>
  <condition>Recurrent Childhood Ependymoma</condition>
  <condition>Recurrent Childhood Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Childhood Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Childhood Malignant Germ Cell Tumor</condition>
  <condition>Recurrent Childhood Medulloblastoma</condition>
  <condition>Recurrent Childhood Pineoblastoma</condition>
  <condition>Recurrent Childhood Small Noncleaved Cell Lymphoma</condition>
  <condition>Recurrent Childhood Subependymal Giant Cell Astrocytoma</condition>
  <condition>Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Childhood Visual Pathway and Hypothalamic Glioma</condition>
  <condition>Recurrent Childhood Visual Pathway Glioma</condition>
  <condition>Recurrent/Refractory Childhood Hodgkin Lymphoma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (vorinostat, bortezomib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral vorinostat once daily on days 1-5 and 8-12 and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (vorinostat, bortezomib)</arm_group_label>
    <other_name>L-001079038</other_name>
    <other_name>SAHA</other_name>
    <other_name>suberoylanilide hydroxamic acid</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vorinostat, bortezomib)</arm_group_label>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>VELCADE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (vorinostat, bortezomib)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (vorinostat, bortezomib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumors, including CNS tumors or lymphoma&#xD;
&#xD;
               -  Histological confirmation not required for the following diagnoses&#xD;
&#xD;
                    -  Intrinsic brain stem tumors&#xD;
&#xD;
                    -  Optic pathway gliomas&#xD;
&#xD;
                    -  Pineal tumors and elevations of cerebral spinal fluid or serum tumor&#xD;
                       markers, including alpha-fetoprotein or beta-human chorionic gonadotropin,&#xD;
                       allowed&#xD;
&#xD;
                    -  Relapsed or refractory disease&#xD;
&#xD;
          -  Must have measurable or evaluable tumor&#xD;
&#xD;
          -  No known curative therapy or therapy proven to prolong survival with an acceptable&#xD;
             quality of life&#xD;
&#xD;
          -  Karnofsky performance status (PS) 60-100% for patients &gt; 16 years of age OR Lansky&#xD;
             PS60-100% for patients ≤ 16 years of age&#xD;
&#xD;
               -  Neurologic deficits inpatients with CNS tumors must have been relatively stable&#xD;
                  for a minimum of 1week&#xD;
&#xD;
               -  Patients who are unable to walk because ofparalysis, but who are up in a&#xD;
                  wheelchair, will be considered ambulatory for thepurpose of assessing the&#xD;
                  performance score&#xD;
&#xD;
          -  ANC ≥ 1,000/μL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL (transfusion independent, defined as not receiving&#xD;
             platelet transfusions within the past 7 days)&#xD;
&#xD;
               -  Patients with known bone marrow metastatic disease allowed provided they meet the&#xD;
                  blood count criteria and are not known to be refractory to platelet transfusion&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)&#xD;
&#xD;
               -  Patients with known bone marrow metastatic disease allowed provided they meet the&#xD;
                  blood count criteria and are not know to be refractory to RBC or platelet&#xD;
                  transfusion&#xD;
&#xD;
          -  Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on age&#xD;
             and/or gender as follows:&#xD;
&#xD;
               -  0.6 mg/dL (1 to &lt; 2 years of age)&#xD;
&#xD;
               -  0.8 mg/dL (2 to &lt; 6 years of age)&#xD;
&#xD;
               -  1.0 mg/dL (6 to &lt; 10 years of age)&#xD;
&#xD;
               -  1.2 mg/dL (10 to &lt; 13 years of age)&#xD;
&#xD;
               -  1.5 (male) or 1.4 (female) (13 to &lt; 16 years of age)&#xD;
&#xD;
               -  1.7 (male) or 1.4 (female) ( ≥ 16 years of age)&#xD;
&#xD;
          -  Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 times upper limit ofnormal&#xD;
&#xD;
          -  ALT ≤ 110 U/L&#xD;
&#xD;
          -  Serum albumin ≥ 2 g/dL&#xD;
&#xD;
          -  QTc interval ≤ 450 milliseconds&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Must be able to swallow capsules or liquids&#xD;
&#xD;
          -  Able to comply withthe safety-monitoring requirements of the study, in the opinion of&#xD;
             the investigator&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2 within the past 14 days&#xD;
&#xD;
          -  No known hypersensitivity to vorinostat or bortezomib&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No concurrent enzyme-inducing anticonvulsants&#xD;
&#xD;
          -  Must be recovered from the acute toxic effects of all prior chemotherapy,&#xD;
             immunotherapy, or radiotherapy&#xD;
&#xD;
          -  More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea)&#xD;
&#xD;
          -  At least 7 days since prior therapy with any of the following:&#xD;
&#xD;
               -  Hematopoietic growth factors&#xD;
&#xD;
               -  Biologic (anti-neoplastic) agent&#xD;
&#xD;
                    -  For agents that have known adverse events occurring beyond 7 days after&#xD;
                       administration, this period must be extended beyond the time during which&#xD;
                       adverse events are known to occur&#xD;
&#xD;
               -  Corticosteroids unless on a stable or decreasing dose&#xD;
&#xD;
          -  At least 7 days or 3 half-lives, whichever is longer, since prior monoclonal&#xD;
             antibodies&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative radiotherapy (small port)&#xD;
&#xD;
          -  At least 6 months since prior total-body irradiation therapy, craniospinal&#xD;
             radiotherapy, or ≥ 50% of pelvis irradiated&#xD;
&#xD;
          -  At least 6 weeks since prior substantial bone marrow radiotherapy&#xD;
&#xD;
          -  At least 3 months since prior stem cell transplantation or rescue and no evidence of&#xD;
             active graft-vs-host disease&#xD;
&#xD;
          -  At least 2 weeks since prior and no concurrent valproic acid&#xD;
&#xD;
          -  At least 6 weeks since priorimmunotherapy (e.g., tumor vaccines)&#xD;
&#xD;
          -  No prior vorinostat&#xD;
&#xD;
          -  No other concurrent investigational drugs or other anticancer agents, including&#xD;
             chemotherapy, radiotherapy, immunotherapy, or biologic therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jodi Muscal</last_name>
    <role>Principal Investigator</role>
    <affiliation>COG Phase I Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>October 10, 2009</study_first_submitted>
  <study_first_submitted_qc>October 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Teratoma</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Endodermal Sinus Tumor</mesh_term>
    <mesh_term>Choriocarcinoma</mesh_term>
    <mesh_term>Craniopharyngioma</mesh_term>
    <mesh_term>Adamantinoma</mesh_term>
    <mesh_term>Choroid Plexus Neoplasms</mesh_term>
    <mesh_term>Pinealoma</mesh_term>
    <mesh_term>Germinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

